Skip to main content
Study: Sustained remission likely in UC patients taking vedolizumab

Ulcerative colitis patients who went into clinical remission four months after beginning treatment with vedolizumab had a better chance of sustaining the remission, according to a study in Inflammatory Bowel Diseases. Clinical remission was evaluated by using a partial Mayo score of at least 2 with no subscore higher than 1 and a rectal bleeding subscore of zero.

Full Story: